我们的目的是研究后腹腔镜无钳位、无缝线混合技术治疗肾门肿瘤的结果和可行性。纳入了 2017 年 1 月至 2021 年 4 月期间接受后腹腔镜无钳位、无缝线混合治疗的连续肾门肿瘤患者的回顾性队列。 。混合手术技术包括微波消融（MWA），随后进行无钳肿瘤摘除术和无缝线止血。记录并分析手术、病理和肿瘤学结果。本研究包括 60 名患者。肿瘤大小中位数为 3.5 cm (2-5)，肾评分中位数为 7（范围 6-10），手术时间中位数为 110 分钟（70-130），估计失血量中位数为 80 mL（30 分钟）。 -130）。术后住院时间中位为 3 天 (2-4)，没有观察到热缺血时间，除了一名患者需要转换为传统钳夹式腹腔镜肾部分切除术 (LPN)，热缺血时间为 10 分钟。术后记录了 3 例轻微并发症（Clavien-Dindo 1 级）和 1 例主要并发症（Clavien-Dindo 3 级）。到目前为止，不需要输血。中位随访 45 个月内未出现肾功能障碍或肿瘤复发。后腹腔镜混合技术包括 MWA、无钳夹肿瘤摘除术和无缝线止血，是治疗选择性肾门肿瘤的可行且安全的选择。可以实现完全肿瘤切除并最大程度保留肾功能，并发症发生率低。© 2023。外科肿瘤学会。

We aimed to investigate the outcomes and feasibility of a retroperitoneoscopic clampless, sutureless hybrid technique in the management of renal hilar tumors.A retrospective cohort of consecutive patients with renal hilar tumors who received retroperitoneoscopic clampless, sutureless hybrid therapy between January 2017 and April 2021 was included. The hybrid surgical technique involved microwave ablation (MWA), followed by clampless tumor enucleation and sutureless hemostasis. Surgical, pathological, and oncological outcomes were recorded and analyzed.Sixty patients were included in this study. The median tumor size was 3.5 cm (2-5), the median RENAL score was 7 (range 6-10), the median operative time was 110 min (70-130), and the median estimated blood loss was 80 mL (30-130). The median length of postoperative hospital stay was 3 days (2-4), and no warm ischemia time was observed, except in one patient who required conversion to conventional on-clamp laparoscopic partial nephrectomy (LPN) with a 10 min warm ischemia time. Three minor complications (Clavien-Dindo grade I) and one major complication (Clavien-Dindo grade III) were recorded postoperatively. Thus far, no blood transfusions have been required. Renal dysfunction or tumor recurrence did not occur within a median follow-up of 45 months.The retroperitoneoscopic hybrid technique involving MWA, clampless tumor enucleation, and sutureless hemostasis is a feasible and safe option for the management of selective renal hilar tumors. Complete tumor removal with maximal renal function preservation can be achieved, with a low complication rate.© 2023. Society of Surgical Oncology.